PHVS

Pharvaris N.V. is a late-stage clinical biopharmaceutical company focused on developing novel oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-mediated diseases. Headquartered in Zug, Switzerland, with operations in the United States and Europe, the company advances its proprietary small molecule platform to address significant unmet medical needs in rare disease populations. Pharvaris's lead product candidate, deucrictibant (PHVS416), is an on-demand treatment for HAE attacks currently in Phase 3 clinical trials, while PHVS719 is being developed as a once-daily prophylactic therapy for HAE prevention. The company's oral formulations aim to provide patients with convenient alternatives to existing injectable and intravenous HAE therapies. Pharvaris completed its merger with Nasdaq-listed Primrose Holdings in July 2021, establishing its public market presence. In 2023, the company reported positive topline results from its DISSOLVE Phase 2 trial of deucrictibant and continues enrollment in pivotal Phase 3 studies. The company maintains collaborations with academic institutions and research organizations to advance its clinical pipeline. Pharvaris employs approximately 100 people across its global operations and maintains a focused strategy on bringing novel oral therapies to the estimated 10,000-15,000 diagnosed HAE patients worldwide while exploring additional indications for its bradykinin receptor antagonist platform.